A: Mixed Connective Tissue Disease (MCTD) is a rare disorder. It shares the features of several conditions, including lupus, myositis (muscle inflammation) and scleroderma. These conditions are all autoimmune diseases, which means the body's defense system mistakenly attacks the body's own tissues. MCTD seems to be an autoimmune disease, too.
If other symptoms develop over time, the patient's diagnosis may "evolve" into MCTD. Symptoms may include:
-A rash on the face, chest or limbs
-Muscle weakness and pain
-Color changes in the fingers triggered by cold (Raynaud's phenomenon)
-Skin thickening, especially on the fingers, hands, forearms and face
-Chest pain made that worsens when taking a deep breath or shortness of breath with exertion
-Fever and fatigue
Blood and urine tests will look for anemia, kidney or muscle inflammation, and an abnormal antibody called anti-ribonuclear protein. These all point toward MCTD.
Treating MCTD depends on which body parts are affected. Corticosteroids (prednisone), hydroxychloroquine (Plaquenil), methotrexate and other immunosuppressive drugs are commonly recommended. Drugs to open up blood vessels, such as nifedipine, are often prescribed for Raynaud's phenomenon. Cyclophosphamide (Cytoxan) or mycophenolate mofetil (CellCept) may be prescribed if kidney inflammation is present. Intravenous immunoglobulin, an injection of antibodies collected from blood donors, may be effective for muscle inflammation.
Most people with rheumatoid arthritis or MCTD can be effectively treated. However, it may take a while to identify the best therapy or combination of treatments.
(Robert H. Shmerling, M.D. is associate physician at Beth Israel Deaconess Medical Center, Boston, Mass., and associate professor at Harvard Medical School. Robert H. He has been a practicing rheumatologist for over 20 years at Beth Israel Deaconess Medical Center. )
(For additional consumer health information, please visit www.health.harvard.edu.)
(c) 2009 PRESIDENT AND FELLOWS OF HARVARD COLLEGE. ALL RIGHTS RESERVED. DISTRIBUTED BY TRIBUNE MEDIA SERVICES, INC.